Advanced glycation: How are we progressing to combat this web of sugar anomalies in diabetic nephropathy

Josephine M. Forbes, Vicki Thallas-Bonke, Mark E. Cooper, Merlin C. Thomas

Research output: Contribution to journalReview ArticleResearchpeer-review

16 Citations (Scopus)


Advanced glycation end products (AGEs) in diabetic nephropathy have been extensively researched over the last decade and are now firmly established as major players in this disease. The enigma remains the search for the ideal AGE inhibition therapy, which is a great challenge in the context of the structural diversity inherent to AGE chemistry. Certainly, there is a requirement to standardize measurements of circulating and tissue levels of AGEs and to characterize the pathogenic potential of specific AGE moieties. In order to develop more effective, targeted approaches to combat diabetic nephropathy, the mechanisms of action of selective AGE inhibitors and the inter-relationships of advanced glycation with other pathogenic pathways must be addressed.

Original languageEnglish
Pages (from-to)3361-3372
Number of pages12
JournalCurrent Pharmaceutical Design
Issue number27
Publication statusPublished - 7 Oct 2004
Externally publishedYes


  • Advanced glycation end products
  • AGE inhibitor
  • CML
  • Cross-link breaker
  • Diabetes
  • Diabetic nephropathy
  • Pentosidine
  • Rage

Cite this